Reminiscence-Based Life Review on Copying With Existential Suffering Among Older Cancer Survivors
Launched by THE UNIVERSITY OF HONG KONG · Aug 30, 2022
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a special program, called a reminiscence-based life review, can help older cancer survivors cope with feelings of existential suffering, which includes questions about the meaning of life and emotional distress. The program involves six sessions where participants will talk about their life experiences and memories. It aims to provide psychological support and improve cognitive function, social support, and overall well-being for those who are 65 years or older and have mild cognitive impairment after cancer treatment.
To participate, individuals must be at least 65 years old, diagnosed with early-stage non-metastatic cancer, and have completed their primary cancer treatment within the past 6 months to 5 years. Participants will be randomly assigned to either receive the reminiscence program or standard care and will be assessed at the beginning, after the sessions, and again six weeks later to see how the program affected their feelings and cognitive function. This trial is currently recruiting participants, and feedback will be collected from those in the intervention group to understand their experiences better.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged ≥ 65 years
- • Diagnosed with stage I-III non-metastatic cancer
- • Completed primary treatment with curative intent (surgery, chemotherapy, and/or radiation therapy) 6 months to 5 years prior to baseline assessments with no recurrence or occurrence of additional cancers
- • identified as mild cognitive impairment by the HK-MoCA 5-Min Protocol cognitive assessment (≤ 7th age and education corrected percentile cutoff score)
- Exclusion Criteria:
- • Inadequate written and verbal Cantonese and/or English comprehension for study activities
- • Diagnosed with dementia
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Mu-Hsing Ho, PhD
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials